Strategies to Prevent Cholera Introduction during International Personnel Deployments: A Computational Modeling Analysis Based on the 2010 Haiti Outbreak


A cholera outbreak modeling study reveals that chemprophylaxis treatment for deployed peacekeepers in Haiti would have reduced the risk of disease introduction by 90%.


Vyšlo v časopise: Strategies to Prevent Cholera Introduction during International Personnel Deployments: A Computational Modeling Analysis Based on the 2010 Haiti Outbreak. PLoS Med 13(1): e32767. doi:10.1371/journal.pmed.1001947
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.pmed.1001947

Souhrn

A cholera outbreak modeling study reveals that chemprophylaxis treatment for deployed peacekeepers in Haiti would have reduced the risk of disease introduction by 90%.


Zdroje

1. Ali M, Lopez AL, Ae You Y, Eun Kim Y, Sah B, et al. The global burden of cholera. Bull World Health Organ. 2012;90: 209–218. doi: 10.2471/BLT.11.093427 22461716

2. Ministère de la santé publique et de la population. Rapport cholera 01 mars 2015. http://bit.ly/1ArOsuT.

3. Jenson D, Szabo V. Cholera in Haiti and other Caribbean regions, 19th century. Emerg Infect Dis. 2011;17: 2130–2135. doi: 10.3201/eid1711.110958 22099117

4. Orata FD, Keim PS, Boucher Y. The 2010 cholera outbreak in Haiti: how science solved a controversy. PLoS Pathog. 2014;10: e1003967 doi: 10.1371/journal.ppat.1003967 24699938

5. Katz LS, Petkau A, Beaulaurier J, Tyler S, Antonova ES, et al. Evolutionary dynamics of Vibrio cholerae O1 following a single-source introduction to Haiti. mBio. 2013;4:e00398–13. doi: 10.1128/mBio.00398-13 23820394

6. Piarroux R, Barrais R, Faucher BB, Haus R, Piarroux M, et al. Understanding the cholera epidemic, Haiti. Emerg Infect Dis. 2011;17:1161–1167. doi: 10.3201/eid1707.110059 21762567

7. Lantagne D, Balakrish Nair G, Lanata CF, Cravioto A. The cholera outbreak in Haiti: Where and how did it begin? Curr Top Microbiol Immunol. 2013;379:145–164.

8. Nelson EJ, Nelson DS, Salam MA, Sack DA. Antibiotics for both moderate and severe cholera. N Engl J Med. 2011;364:5–7. doi: 10.1056/NEJMp1013771 21142691

9. Reveiz L, Chapman E, Ramon-Pardo P, Koehlmoos TP, Cuervo LG, et al. Chemoprophylaxis in contacts of patients with cholera: systematic review and meta-analysis. PLoS ONE. 2011;6:e2760.

10. Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet. 1994;344:1273–1276. 7967990

11. Black RE, Levine MM, Clements ML, Young CR, Svennerholm AM, et al. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun. 1987;55:1116–1120. 3552989

12. United Nations follow-up to the recommendations of the Independent Panel of Expertos on the Cholera Outbreak in Haiti. http://www.un.org/News/dh/infocus/haiti/Follow-up-to-Recommendations-of-IPE.pdf.

13. Medrano Rojas P. Assistant Secretary General’s response. http://bit.ly/1Sw6O3z.

14. Hughes JM, Boyce JM, Levine RJ, Khan M, Aziz KM, et al. Epidemiology of El Tor cholera in rural Bangladesh: importance of surface water in transmission. Bull World Health Organ. 1982;60:395–404. 6982775

15. Bart KJ, Huq Z, Khan M, Mosley WH. Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis. 1970;121:17–24. 4912068

16. Woodward WE, Mosley WH. The spectrum of cholera in rural Bangladesh: comparison of El Tor Ogawa and classical Inaba infection. Am J Epidemiol. 1972;96:342–351. 4564735

17. Tamayo JF, Mosley WH, Alvero MG, Joseph PR, Gomez CZ, et al. Studies of cholera El Tor in the Philippines. Bull World Health Organ. 1965;33:645–649. 5295145

18. Glass RI, Holmgren J, Haley CE, Khan MR, Svennerholm AM, et al. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol. 1985;121: 791–796. 4014172

19. Weil AA, Khan AI, Chowdhury F, Larocque RC, Faruque ASG, et al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin Infect Dis. 2009;49: 1473–1479. doi: 10.1086/644779 19842974

20. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36: 1–48.

21. Ernst S, Weinrobe C, Bien-Aime C, Rawson I. Cholera management and prevention at Hôpital Albert Schweitzer, Haiti. Emerg Infect Dis. 2011;17: 2155–2157. doi: 10.3201/eid1711.110815 22099123

22. Update: outbreak of cholera—Haiti, 2010. Morbid Mortal Wkly Rep. 2010;59:1586–1590.

23. Grad YH, Miller JC, Lipsitch M. Cholera modeling: challenges to quantitative analysis and predicting the impact of interventions. Epidemiology. 2012;23: 523–530. doi: 10.1097/EDE.0b013e3182572581 22659546

24. Chao DL, Longini IM, Morris JG. Modeling cholera outbreaks. Curr Top Microbiol Immunol. 2014;379: 195–209. doi: 10.1007/82_2013_307 23412687

25. Gaudart J, Rebaudet S, Barrais R, Boncy J, Faucher B, et al. Spatio-temporal dynamics of cholera during the first year of the epidemic in Haiti. PLoS Negl Trop Dis. 2013;7: e0002145.

26. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, et al. Cholera surveillance during the Haiti epidemic—the first 2 years. N Engl J Med. 2013;368: 599–609. doi: 10.1056/NEJMoa1204927 23301694

27. Azman AS, Rudolph KE, Cummings DAT, Lessler J. The incubation period of cholera: A systematic review. J Infect. 2013;66: 432–438. doi: 10.1016/j.jinf.2012.11.013 23201968

28. Alam NH, Ashraf H, Khan WA, Karim MM, Fuchs GJ. Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial. Gut. 2003;52: 1419–1423. 12970133

29. Dutta D, Bhattacharya SK, Bhattacharya MK, Deb A, Deb M, et al. Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae O139 infection. J Antimicrob Chemother. 1996;37: 575–581. 9182114

30. Leibovici-Weissman Y, Neuberger A, Bitterman R, Sinclair D, Salam MA, et al. Antimicrobial drugs for treating cholera. Cochrane database Syst Rev. 2014;6: CD008625 doi: 10.1002/14651858.CD008625.pub2 24944120

31. Patra FC, Majumder RN, Eeckels R, Desjeux JF, Mahalanabis D. Sacolene in cholera: a double blind randomized controlled trial. Scand J Infect Dis. 1999;31: 151–154. 10447324

32. Rabbani GH, Islam MR, Butler T, Shahrier M, Alam K. Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial. Antimicrob Agents Chemother. 1989;33: 1447–1450. 2684006

33. Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ. 1967;36: 871–883. 4865453

34. Shahadat Hossain M, Salam MA, Rabbani GH, Kabir I, Biswas R, et al. Tetracycline in the treatment of severe cholera due to Vibrio cholerae O139 Bengal. J Heal Popul Nutr. 2002;20: 18–25.

35. Hartley DM, Morris JG, Smith DL. Hyperinfectivity: A critical element in the ability of V. cholerae to cause epidemics?. PLoS Med. 2006;3: 63–69.

36. Merrell DS, Butler SM, Qadri F, Dolganov Na, Alam A, et al. Host-induced epidemic spread of the cholera bacterium. Nature. 2002;417: 642–645. 12050664

37. Alam A, Larocque RC, Harris JB, Vanderspurt C, Ryan ET, et al. Hyperinfectivity of Human-Passaged Vibrio cholerae can be modeled by growth in the infant mouse. Infect Immun. 2005;73: 6674–6679. 16177344

38. Cash RA, Music SI, Libonati JP, Snyder MJ, Wenzel RP, et al. Response of man to infection with Vibrio cholerae. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis. 1974;129: 45–52. 4809112

39. Sack DA, Tacket CO, Cohen MB, Sack RB, Losonsky Ga., et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun. 1998;66: 1968–1972. 9573077

40. Rendtorff RC, Kashgarian M. Stool patterns of healthy adult males. Dis Colon Rectum. 1953;10: 222–228.

41. Haiti 2009 population data, section estimates, stratified by age and sex. Centers for Disease Control and Prevention 2012. http://www.cdc.gov/haiticholera/.

42. Clements ML, Levine MM, Young CR, Black RE, Lim YL, et al. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982;145: 465–473. 7069227

43. Jackson BR, Talkington DF, Pruckler JM, Fouché MDB, Lafosse E, et al. Seroepidemiologic survey of epidemic cholera in Haiti to assess spectrum of illness and risk factors for severe disease. Am J Trop Med Hyg. 2013;89: 654–664. doi: 10.4269/ajtmh.13-0208 24106192

44. Chao DL, Halloran ME, Longini IM. Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci U S A. 2011;108: 7081–7085. doi: 10.1073/pnas.1102149108 21482756

45. Bhuiyan NA, Qadri F, Faruque ASG, Malek MA, Salam MA, et al. Use of dipsticks for rapid diagnosis of cholera caused by Vibrio cholerae O1 and O139 from rectal swabs. J Clin Microbiol. 2003;41: 3939–3941. 12904424

46. Chakraborty S, Alam M, Scobie HM, Sack DA. Adaptation of a simple dipstick test for detection of Vibrio cholerae O1 and O139 in environmental water. Front Microbiol. 2013;4: 1–3.

47. Dick MH, Guillerm M, Moussy F, Chaignat CL. Review of two decades of cholera diagnostics: how far have we really come? PLoS Negl Trop Dis. 2012;6: e0001845.

48. McCormack WM, Chowdhury AM, Jahangir N. Tetracycline prophylaxis in families of cholera patients. Bull World Health Organ. 1967;38: 787–792

49. Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006;354: 2452–2462. 16760445

50. Levine M, Herrington D, Losonsky G, Tall B, Kaper J, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988;332: 467–470.

51. Shin S, Desai SN, Sah BK, Clemens JD. Oral vaccines against cholera. Clin Infect Dis. 2011;52: 1343–1349. doi: 10.1093/cid/cir141 21498389

52. Echevarría J, Seas C, Carrillo C, Mostorino R, Ruiz R, et al. Efficacy and tolerability of ciprofloxacin prophylaxis in adult household contacts of patients with cholera. Clin Infect Dis. 1995;20: 1480–1484. 7548495

53. International Drug Price Indicator Guide. Medford, Massachusetts, US: Management Sciences for Health. 2014.

54. Guidance on how to access the Oral Cholera Vaccine (OCV) from the ICG emergency stockpile. http://www.who.int/cholera/vaccines/Guidance_accessing_OCV_stockpile.pdf?ua=1.

55. Gillespie DT. Exact stochastic simulation of coupled chemical reactions. J Phys Chem. 1977;81: 2340–2361.

56. Van Den Driessche P, Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math Biosci. 2002;180: 29–48. 12387915

57. Ivers LC, Walton DA. The “first” case of cholera in Haiti: Lessons for global health. Am J Trop Med Hyg. 2012;86: 36–38. doi: 10.4269/ajtmh.2012.11-0435 22232448

58. Harris JR, Cavallaro EC, De Nóbrega AA, Jean JCB, Bopp C, et al. Field evaluation of crystal VC rapid dipstick test for cholera during a cholera outbreak in Guinea-Bissau. Trop Med Int Heal. 2009;14: 1117–1121.

59. Crystal VC (Dipstick) immunochromatographic test for detection of V. cholerae in stool (rapid test). SPAN Diagnostics. http://www.span.co.in/ProductList/ProductDetails/REAGENTS/279-Crystal_VC_(Dipstick).HTM.

60. Farmer P, Almazor CP, Bahnsen ET, Barry D, Bazile J, et al. Meeting Cholera’s challenge to Haiti and the world: A joint statement on cholera prevention and care. PLoS Negl Trop Dis. 2011;5: e0001145.

61. Chretien JP, Blazes DL, Coldren RL, Lewis MD, Gaywee J, et al. The importance of militaries from developing countries in global infectious disease surveillance. Bull World Health Organ. 2007;85: 174–180. 17486207

62. Steffen R. Immunization of peacekeeping forces. Emerg Infect Dis. 1999;5: 485–486. 10341196

63. Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis. 2007;13: 1640–1646. doi: 10.3201/eid1311.070674 18217545

64. Faruque ASG, Alam K, Malek Ma, Khan MGY, Ahmed S, et al. Emergence of multidrug-resistant strain of Vibrio cholerae OI in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Heal Popul Nutr. 2007;25: 241–243.

65. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet. 2012;379: 2466–2476. doi: 10.1016/S0140-6736(12)60436-X 22748592

66. Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, et al. The origin of the Haitian cholera outbreak strain. N Engl J Med. 2011;364: 33–42. doi: 10.1056/NEJMoa1012928 21142692

67. Ali A, Chen Y, Johnson JA, Redden E, Mayette Y, et al. Recent clonal origin of cholera in Haiti. Emerg Infect Dis. 2011;17: 699–701. doi: 10.3201/eid1704.101973 21470464

68. Constantin de Magny G, Murtugudde R, Sapiano MRP, Nizam A, Brown CW, et al. Environmental signatures associated with cholera epidemics. Proc Natl Acad Sci U S A. 2012;105: 17676–17681.

69. Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack Da., et al. The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study. PLoS Med. 2015;12: e1001867. doi: 10.1371/journal.pmed.1001867 26305226

70. Reyburn R, Deen JL, Grais RF, Bhattacharya SK, Sur D, et al. The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis. 2011;5: e952. doi: 10.1371/journal.pntd.0000952 21283614

71. Houston S, Houston A. Screening and Treating UN Peacekeepers to Prevent the Introduction of Artemisinin-Resistant Malaria into Africa. PLoS Med. 2015;12: e1001822. doi: 10.1371/journal.pmed.1001822 25942008

72. Watson JT, Gayer M, Connolly MA. Epidemics after natural disasters. Emerg Infect Dis. 2007;13: 1–5. 17370508

73. Dowell SF, Braden CR. Implications of the introduction of cholera to Haiti. Emerg Infect Dis. 2011;17: 1299–1300. 21762593

74. United Nations Peacekeeping. Troop and police contributors. http://www.un.org/en/peacekeeping/resources/statistics/contributors.shtml.

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2016 Číslo 1
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Získaná hemofilie - Povědomí o nemoci a její diagnostika

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa